Advances in diagnosis and treatment of bladder cancer
Open accessThe DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.
Abstract
Bladder cancer remains a leading cause of cancer death worldwide and is associated with substantial impacts on patient quality of life, morbidity, mortality, and cost to the healthcare system. Gross hematuria frequently precedes the diagnosis of bladder cancer. Non-muscle-invasive bladder cancer (NMIBC) is managed initially with transurethral resection of a bladder tumor (TURBT), followed by a risk stratified approach to adjuvant intravesical therapy (IVe), and is associated with an overall survival of 90%. However, cure rates remain lower for muscle invasive bladder cancer (MIBC) owing to a variety of factors. NMIBC and MIBC groupings are heterogeneous and have unique pathological and molecular characteristics. Indeed, The Cancer Genome Atlas project identified genetic drivers and luminal and basal molecular subtypes of MIBC with distinct treatment responses. For NMIBC, IVe immunotherapy (primarily BCG) is the gold standard treatment for high grade and high risk NMIBC to reduce or prevent both recurrence and progression after initial TURBT; novel trials incorporate immune checkpoint inhibitors. IVe gene therapy and combination IVe chemotherapy have recently been completed, with promising results. For localized MIBC, essential goals are improving care and reducing morbidity following cystectomy or bladder preserving strategies. In metastatic disease, advances in understanding of the genomic landscape and tumor microenvironment have led to the implementation of immune checkpoint inhibitors, targeted treatments, and antibody-drug conjugates. Defining better selection criteria to identify the patients most likely to benefit from a specific treatment is an urgent need.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
The National Comprehensive Cancer Network: Present and future directions
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-a · Cited by 16,766
Siegel, R. L., Giaquinto, A. N., & Jemal, A. (2024) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21820 · Cited by 9,533
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400 · cited 1×
“92 The role of biomarker testing to guide immune checkpoint inhibitor remains uncertain, because PD1/PDL1 as a single biomarker to predict immune checkpoint inhibitor response might not be sufficient.”
BackgroundPembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Bellmunt, J., de Wit, R., Vaughn, D. J., Fradet, Y., Lee, J.-L., Fong, L., Vogelzang, N. J., Climent, M. A., Petrylak, D. P., Choueiri, T. K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613683 · Cited by 3,395
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
Modi, S., Jacot, W., Yamashita, T., Sohn, J., Vidal, M., Tokunaga, E., Tsurutani, J., Ueno, N. T., Prat, A., Chae, Y. S., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2203690 · Cited by 2,664
von der Maase, H., Hansen, S. W., Roberts, J. T., Dogliotti, L., Oliver, T., Moore, M. J., Bodrogi, I., Albers, P., Knuth, A., Lippert, C. M., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.17.3068 · Cited by 2,279
Babjuk, M., Burger, M., Capoun, O., Cohen, D., Compérat, E. M., Dominguez Escrig, J. L., Gontero, P., Liedberg, F., Masson-Lecomte, A., Mostafid, A. H., et al. (2022) · European Urology · doi:10.1016/j.eururo.2021.08.010 · Cited by 1,615
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
Powles, T., Park, S. H., Voog, E., Caserta, C., Valderrama, B. P., Gurney, H., Kalofonos, H., Radulović, S., Demey, W., Ullén, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002788 · Cited by 1,493
Kamat, A. M., Hahn, N. M., Efstathiou, J. A., Lerner, S. P., Malmström, P.-U., Choi, W., Guo, C. C., Lotan, Y., & Kassouf, W. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30512-8 · Cited by 1,421
Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
Loriot, Y., Necchi, A., Park, S. H., Garcia-Donas, J., Huddart, R., Burgess, E., Fleming, M., Rezazadeh, A., Mellado, B., Varlamov, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817323 · Cited by 1,360
Vale, C. L. (2005) · European Urology · doi:10.1016/j.eururo.2005.04.006 · Cited by 1,325
Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma
Powles, T., Rosenberg, J. E., Sonpavde, G. P., Loriot, Y., Durán, I., Lee, J.-L., Matsubara, N., Vulsteke, C., Castellano, D., Wu, C., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035807 · Cited by 1,229
Meric-Bernstam, F., Makker, V., Oaknin, A., Oh, D.-Y., Banerjee, S., González-Martín, A., Jung, K. H., Ługowska, I., Manso, L., Manzano, A., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02005 · Cited by 1,069
Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma
Bajorin, D. F., Witjes, J. A., Gschwend, J. E., Schenker, M., Valderrama, B. P., Tomita, Y., Bamias, A., Lebret, T., Shariat, S. F., Park, S. H., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2034442 · Cited by 1,065
Radiotherapy with or without Chemotherapy in Muscle-Invasive Bladder Cancer
James, N. D., Hussain, S. A., Hall, E., Jenkins, P., Tremlett, J., Rawlings, C., Crundwell, M., Sizer, B., Sreenivasan, T., Hendron, C., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1106106 · Cited by 962
Sanli, O., Dobruch, J., Knowles, M. A., Burger, M., Alemozaffar, M., Nielsen, M. E., & Lotan, Y. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.22 · Cited by 814
Seiler, R., Ashab, H. A. D., Erho, N., van Rhijn, B. W. G., Winters, B., Douglas, J., Van Kessel, K. E., Fransen van de Putte, E. E., Sommerlad, M., Wang, N. Q., et al. (2017) · European Urology · doi:10.1016/j.eururo.2017.03.030 · Cited by 786
Advances in bladder cancer biology and therapy
Tran, L., Xiao, J.-F., Agarwal, N., Duex, J. E., & Theodorescu, D. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00313-1 · Cited by 735
Powles, T., Csőszi, T., Özgüroğlu, M., Matsubara, N., Géczi, L., Cheng, S. Y.-S., Fradet, Y., Oudard, S., Vulsteke, C., Morales Barrera, R., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00152-2 · Cited by 643
Dyrskjøt, L., Hansel, D. E., Efstathiou, J. A., Knowles, M. A., Galsky, M. D., Teoh, J., & Theodorescu, D. (2023) · Nature Reviews Disease Primers · doi:10.1038/s41572-023-00468-9 · Cited by 544
Tagawa, S. T., Balar, A. V., Petrylak, D. P., Kalebasty, A. R., Loriot, Y., Fléchon, A., Jain, R. K., Agarwal, N., Bupathi, M., Barthelemy, P., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03489 · Cited by 543
Epidemiology of Bladder Cancer in 2023: A Systematic Review of Risk Factors
Jubber, I., Ong, S., Bukavina, L., Black, P. C., Compérat, E., Kamat, A. M., Kiemeney, L., Lawrentschuk, N., Lerner, S. P., Meeks, J. J., et al. (2023) · European Urology · doi:10.1016/j.eururo.2023.03.029 · Cited by 521
Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma
van der Heijden, M. S., Sonpavde, G., Powles, T., Necchi, A., Burotto, M., Schenker, M., Sade, J. P., Bamias, A., Beuzeboc, P., Bedke, J., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2309863 · Cited by 511
Mak, R. H., Hunt, D., Shipley, W. U., Efstathiou, J. A., Tester, W. J., Hagan, M. P., Kaufman, D. S., Heney, N. M., & Zietman, A. L. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.5548 · Cited by 465
Efstathiou, J. A., Spiegel, D. Y., Shipley, W. U., Heney, N. M., Kaufman, D. S., Niemierko, A., Coen, J. J., Skowronski, R. Y., Paly, J. J., McGovern, F. J., et al. (2012) · European Urology · doi:10.1016/j.eururo.2011.11.010 · Cited by 435
Epidemiology, Screening, and Prevention of Bladder Cancer
Lobo, N., Afferi, L., Moschini, M., Mostafid, H., Porten, S., Psutka, S. P., Gupta, S., Smith, A. B., Williams, S. B., & Lotan, Y. (2022) · European Urology Oncology · doi:10.1016/j.euo.2022.10.003 · Cited by 372
Galsky, M. D., Hahn, N. M., Rosenberg, J., Sonpavde, G., Hutson, T., Oh, W. K., Dreicer, R., Vogelzang, N., Sternberg, C., Bajorin, D. F., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70275-8 · Cited by 356
Catto, J. W. F., Khetrapal, P., Ricciardi, F., Ambler, G., Williams, N. R., Al-Hammouri, T., Khan, M. S., Thurairaja, R., Nair, R., Feber, A., et al. (2022) · JAMA · doi:10.1001/jama.2022.7393 · Cited by 345
Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma
Loriot, Y., Matsubara, N., Park, S. H., Huddart, R. A., Burgess, E. F., Houede, N., Banek, S., Guadalupi, V., Ku, J. H., Valderrama, B. P., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2308849 · Cited by 340
Bellmunt, J., Paz-Ares, L., Cuello, M., Cecere, F. L., Albiol, S., Guillem, V., Gallardo, E., Carles, J., Mendez, P., de la Cruz, J. J., et al. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl435 · Cited by 319
NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022: Featured Updates to the NCCN Guidelines
Flaig, T. W., Spiess, P. E., Abern, M., Agarwal, N., Bangs, R., Boorjian, S. A., Buyyounouski, M. K., Chan, K., Chang, S., Friedlander, T., et al. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.0041 · Cited by 296
Yu, E. Y., Petrylak, D. P., O'Donnell, P. H., Lee, J.-L., van der Heijden, M. S., Loriot, Y., Stein, M. N., Necchi, A., Kojima, T., Harrison, M. R., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00094-2 · Cited by 287
Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer
Hoimes, C. J., Flaig, T. W., Milowsky, M. I., Friedlander, T. W., Bilen, M. A., Gupta, S., Srinivas, S., Merchan, J. R., McKay, R. R., Petrylak, D. P., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01643 · Cited by 285
Powles, T., Park, S. H., Caserta, C., Valderrama, B. P., Gurney, H., Ullén, A., Loriot, Y., Sridhar, S. S., Sternberg, C. N., Bellmunt, J., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01792 · Cited by 229
Klümper, N., Ralser, D. J., Ellinger, J., Roghmann, F., Albrecht, J., Below, E., Alajati, A., Sikic, D., Breyer, J., Bolenz, C., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1764 · Cited by 227
Pfister, C., Gravis, G., Fléchon, A., Chevreau, C., Mahammedi, H., Laguerre, B., Guillot, A., Joly, F., Soulié, M., Allory, Y., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02051 · Cited by 215
O'Donnell, P. H., Milowsky, M. I., Petrylak, D. P., Hoimes, C. J., Flaig, T. W., Mar, N., Moon, H. H., Friedlander, T. W., McKay, R. R., Bilen, M. A., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.02887 · Cited by 196
Sheng, X., Wang, L., He, Z., Shi, Y., Luo, H., Han, W., Yao, X., Shi, B., Liu, J., Hu, C., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.22.02912 · Cited by 185
IL-15 Superagonist NAI in BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer
Chamie, K., Chang, S. S., Kramolowsky, E., Gonzalgo, M. L., Agarwal, P. K., Bassett, J. C., Bjurlin, M., Cher, M. L., Clark, W., Cowan, B. E., et al. (2023) · NEJM Evidence · doi:10.1056/evidoa2200167 · Cited by 177
Siefker-Radtke, A. O., Necchi, A., Park, S. H., García-Donas, J., Huddart, R. A., Burgess, E. F., Fleming, M. T., Rezazadeh Kalebasty, A., Mellado, B., Varlamov, S., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00660-4 · Cited by 171
Rosenberg, J. E., Powles, T., Sonpavde, G. P., Loriot, Y., Duran, I., Lee, J.-L., Matsubara, N., Vulsteke, C., Castellano, D., Mamtani, R., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.08.016 · Cited by 171
Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes
Sjödahl, G., Abrahamsson, J., Holmsten, K., Bernardo, C., Chebil, G., Eriksson, P., Johansson, I., Kollberg, P., Lindh, C., Lövgren, K., et al. (2022) · European Urology · doi:10.1016/j.eururo.2021.10.035 · Cited by 170
Iyer, G., Balar, A. V., Milowsky, M. I., Bochner, B. H., Dalbagni, G. M., Donat, S. M., Herr, H. W., Huang, W. C. W., Taneja, S. S., Woods, M. E., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.0158 · Cited by 150
Defining cisplatin eligibility in patients with muscle-invasive bladder cancer
Jiang, D., Gupta, S., Kitchlu, A., Meraz-Muñoz, A., North, S. A., Alimohamed, N. S., Blais, N., & Sridhar, S. S. (2021) · Nature Reviews Urology · doi:10.1038/s41585-020-00404-6 · Cited by 144
Burdett, S., Fisher, D. J., Vale, C. L., Sternberg, C. N., Clarke, N. W., Parmar, M., Bono, A. V., Cognetti, F., Collette, L., Côté, R. J., et al. (2021) · European Urology · doi:10.1016/j.eururo.2021.09.028 · Cited by 139
Powles, T. B., Valderrama, B. P., Gupta, S., Bedke, J., Kikuchi, E., Hoffman-Censits, J. H., Iyer, G., Vulsteke, C., Park, S. H., Shin, S. J., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.10.106 · Cited by 137
de Jong, F. C., Laajala, T. D., Hoedemaeker, R. F., Jordan, K. R., van der Made, A. C. J., Boevé, E. R., van der Schoot, D. K. E., Nieuwkamer, B. B., Janssen, E. A. M., Mahmoudi, T., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abn4118 · Cited by 111
Siefker-Radtke, A. O., Matsubara, N., Park, S. H., Huddart, R. A., Burgess, E. F., Özgüroğlu, M., Valderrama, B. P., Laguerre, B., Basso, U., Triantos, S., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.10.003 · Cited by 102
Flaig, T. W., Tangen, C. M., Daneshmand, S., Alva, A. S., Lerner, S. P., Lucia, M. S., McConkey, D. J., Theodorescu, D., Goldkorn, A., Milowsky, M. I., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2409 · Cited by 99
Petrylak, D. P., de Wit, R., Chi, K. N., Drakaki, A., Sternberg, C. N., Nishiyama, H., Castellano, D., Hussain, S. A., Fléchon, A., Bamias, A., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30668-0 · Cited by 94
Artificial intelligence: A promising frontier in bladder cancer diagnosis and outcome prediction
Borhani, S., Borhani, R., & Kajdacsy‐Balla, A. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103601 · Cited by 88
Molecular changes during progression from nonmuscle invasive to advanced urothelial carcinoma
Sjödahl, G., Eriksson, P., Patschan, O., Marzouka, N., Jakobsson, L., Bernardo, C., Lövgren, K., Chebil, G., Zwarthoff, E. C., Liedberg, F., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32737 · Cited by 80
Molecular pathology of urothelial carcinoma
Antonio Lopez-beltran, B., Cimadamore, A., Montironi, R., & Liang Cheng, C. (2021) · Human Pathology · doi:10.1016/j.humpath.2021.04.001 · Cited by 73
Hurst, C. D., Cheng, G., Platt, F. M., Castro, M. A. A., Marzouka, N., Eriksson, P., Black, E. V. I., Alder, O., Lawson, A. R. J., Lindskrog, S. V., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100472 · Cited by 69
Lotan, Y., de Jong, J. J., Liu, V. Y. T., Bismar, T. A., Boorjian, S. A., Huang, H.-C., Davicioni, E., Mian, O. Y., Wright, J. L., Necchi, A., et al. (2021) · The Journal of Urology · doi:10.1097/ju.0000000000002261 · Cited by 67
Cheng, L., Zhang, S., Wang, M., & López-Beltrán, A. (2022) · Human Pathology · doi:10.1016/j.humpath.2022.06.005 · Cited by 61
Self-citationPrecision Medicine in Bladder Cancer: Present Challenges and Future Directions
Mohanty, S. K., Lobo, A., Mishra, S. K., & Cheng, L. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13050756 · Cited by 55
Self-citationImmune Checkpoint Inhibitors — The Need for Innovation
Johnson, P. C., Gainor, J. F., Sullivan, R. J., Longo, D. L., & Chabner, B. A. (2023) · New England Journal of Medicine · doi:10.1056/nejmsb2300232 · Cited by 54
Damrauer, J. S., Roell, K. R., Smith, M. A., Sun, X., Kirk, E. L., Hoadley, K. A., Benefield, H. C., Iyer, G., Solit, D. B., Milowsky, M. I., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0205 · Cited by 52
Targetable Pathways in Advanced Bladder Cancer: FGFR Signaling
Xiao, J.-F., Caliri, A. W., Duex, J. E., & Theodorescu, D. (2021) · Cancers · doi:10.3390/cancers13194891 · Cited by 51
Kollberg, P., Chebil, G., Eriksson, P., Sjödahl, G., & Liedberg, F. (2019) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2019.04.010 · Cited by 45
Molecularly Targeted Therapy towards Genetic Alterations in Advanced Bladder Cancer
Thomas, J. V., & Sonpavde, G. (2022) · Cancers · doi:10.3390/cancers14071795 · Cited by 42
Antonio Lopez-beltran, B., Blanca, A., Cimadamore, A., Gogna, R., Montironi, R., & Liang Cheng, C. (2021) · Cancers · doi:10.3390/cancers13215500 · Cited by 39
Al‐Obaidy, K. I., & Liang Cheng, C. (2021) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2020-207115 · Cited by 38
Antonio Lopez-beltran, B., López‐Ríos, F., Montironi, R., Wildsmith, S., & Eckstein, M. (2021) · Cancers · doi:10.3390/cancers13061424 · Cited by 37
Developing Precision Medicine for Bladder Cancer
Guercio, B. J., Iyer, G., & Rosenberg, J. E. (2021) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2021.02.008 · Cited by 30
Self-citationHong, M. L. W., He, G. S., Goh, S., Low, A. W. X., Tay, K. J., Lim, T. K. H., Yeong, J. P.-S., Khor, L. Y., & Lim, T. S. (2021) · Cancers · doi:10.3390/cancers13020260 · Cited by 29
Molecular Characterization of Residual Bladder Cancer after Neoadjuvant Pembrolizumab
Necchi, A., de Jong, J. J., Raggi, D., Briganti, A., Marandino, L., Andrea Gallina, A., Bandini, M., Dabbas, B., Davicioni, E., Umberto Capitanio, A., et al. (2021) · European Urology · doi:10.1016/j.eururo.2021.03.014 · Cited by 29
Ürün, Y., Leow, J. J. J., Fay, A. P., Albiges, L. K., Choueiri, T. K., & Joaquim Bellmunt, B. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.10.012 · Cited by 28
EphrinB2 Inhibition and Pembrolizumab in Metastatic Urothelial Carcinoma
Sadeghi, S., Quinn, D. I., Dorff, T. B., Pal, S. K., Groshen, S. G., Tsao-Wei, D. D., Parikh, R. A., Devitt, M. E., Parikh, M., Jackovich, A., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02923 · Cited by 23
Tackling non-muscle invasive bladder cancer in the clinic
Woldu, S. L., Şanlı, Ö., & Lotan, Y. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1313119 · Cited by 22
Konieczkowski, D. J., Efstathiou, J. A., & Mouw, K. W. (2021) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2021.02.006 · Cited by 21
Siefker-Radtke, A. O., Cho, D. C., Diab, A. K., Sznol, M., Bilen, M. A., Balar, A. V., Grignani, G., Puente-Poushnejad, E., Tang, L., Chien, D. C., et al. (2022) · European Urology · doi:10.1016/j.eururo.2022.05.002 · Cited by 21
Risk Classification of Bladder Cancer by Gene Expression and Molecular Subtype
Blanca, A., Antonio Lopez-beltran, B., Lopez-Porcheron, K., Gómez‐Gómez, E., Cimadamore, A., Bilé-Silva, A., Gogna, R., Montironi, R., & Liang Cheng, C. (2023) · Cancers · doi:10.3390/cancers15072149 · Cited by 21
Real World Outcomes of Patients with Bladder Cancer
Pfail, J. L., Small, A., Cumarasamy, S., & Galsky, M. D. (2021) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2021.01.005 · Cited by 20
Targeting the FGFR Pathway in Urothelial Carcinoma: the Future Is Now
Peng, J., Sridhar, S. S., Siefker-Radtke, A. O., Selvarajah, S., & Jiang, D. (2022) · Current Treatment Options in Oncology · doi:10.1007/s11864-022-01009-4 · Cited by 20
Therapy for Muscle-Invasive Urothelial Carcinoma: Controversies and Dilemmas
Sonpavde, G., Mouw, K. W., & Mossanen, M. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02928 · Cited by 18
Cheng, L., López-Beltrán, A., Wang, M., Whaley, R. D., Souza, A. D., Au, S., Ge, R., Cimadamore, A., Amin, A., Golijanin, B., et al. (2023) · Modern Pathology · doi:10.1016/j.modpat.2023.100151 · Cited by 16
Self-citationTripathi, A., MacDougall, K. N., & Sonpavde, G. (2022) · Drugs · doi:10.1007/s40265-022-01802-3 · Cited by 14
Emerging Targeted Therapy for Bladder Cancer
Thibault, C., & Loriot, Y. (2021) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2021.02.011 · Cited by 11
Current Therapy for Metastatic Urothelial Carcinoma
Nadal, R., Clara, J., Valderrama, B. P., & Joaquim Bellmunt, B. (2021) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2021.02.010 · Cited by 11
Current Perioperative Therapy for Muscle Invasive Bladder Cancer
Ma, J., & Black, P. C. (2021) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2021.02.002 · Cited by 8
Bilé-Silva, A., López-Beltrán, A., Blanca, A., López‐Ríos, F., Gómez‐Gómez, E., Cimadamore, A., Montironi, R., Vau, N., & Cheng, L. (2023) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2023.2201371 · Cited by 8
Self-citationMolecular Biology of Bladder Cancer
McConkey, D. J. (2021) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2021.02.009 · Cited by 6
Cited by
Cancer treatment and survivorship statistics, 2025
Wagle, N. S., Nogueira, L., Devasia, T. P., Mariotto, A. B., Yabroff, K. R., Islami, F., Jemal, A., Alteri, R., Ganz, P. A., & Siegel, R. L. (2025) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.70011 · Cited by 261
TBX3 shapes an immunosuppressive microenvironment and induces immunotherapy resistance
Liu, Z., Zhang, C., Xiao, J., He, Y., Liang, H., Huang, J., Cai, Z., Yi, Z., Chen, M., Li, Y., et al. (2025) · Theranostics · doi:10.7150/thno.103175 · Cited by 8
Metadata
- Authors
- Lopez-Beltran, A., Cookson, M. S., Guercio, B. J., & Cheng, L.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2024-02-12
- Volume
- 384
- Pages
- e076743
- ISSN
- 1756-1833 (ISSN-L)
- OpenAlex
- W4391744412
- Cited by
- 496
- References
- 85
- FWCI
- 189.35
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.